14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Signals

$0.255
+0 (+0%)
At Close: May 27, 2022

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 63 days ( 0 % )
Last Price $0.255 0 %
High/ Low $0.255 - $0.255 0%
Chg 7 Days N/A $0.255 $0.255
Chg 30 Days N/A $0.255 $0.255
Chg 12 mos -74.50 % $1.00 $0.255
Trend - 3 mos 0.570 % Width: 6.48 %
Trend - 12 mos -78.77 % Width: 368.71 %
Pred. range - 3 mos $0.242 - $0.257 -5.20 % - 0.94 %
Pred. range - 12 mos N/A - $0.0543 -100.00 % - -78.70 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Buy Mar 02, 2022 - 62 days
Short MA avg 12 mos Buy Feb 24, 2022 - 66 days
Long MA avg 12 mos Buy May 25, 2022 - 3 days
Short/Long MA avg 12 mos Buy May 25, 2022 - 3 days
Pivot Short Sell May 26, 2022 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT